Company Analysis
Sign in

NovaBridge Biosciences (NBP)

Nasdaq: NBP · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.6
◀ Past 5.1● Present 2.7▶ Future 5.9
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of NovaBridge Biosciences

Nine metrics read from its own filings, by tense
Headline grade
4.6/10
◀ Past5.125% of the headline
● Present2.735% of the headline
▶ Future5.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2019.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

NovaBridge Biosciences' filings since 2019 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
2.0/10

What has it actually done, year after year?

-73.9% a year over 4 filed years; profitable in 1 of 4.

weight 45% of this tense · 20th percentile among 323 sector filers · read for its customers

From the record

NovaBridge Biosciences' 4 filed years say what it did: revenue went from CNY 1.5 billion in fiscal 2020 to CNY 28 million in fiscal 2023, down 73.9% a year; it rose in 0 of 2 years; the deepest fall was 114% from fiscal 2020 to fiscal 2022; net income was positive in 1 of 4 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-73.9%bottom 1% of its family
  • the share of years revenue rosebottom 4% of its family
  • the share of filed years with a profittop 24% of its family
  • the deepest fall from a revenue peak114.4%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
7.1/10

How has it treated the people who own it?

SI estimate 7.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 71st percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 29% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: NovaBridge Biosciences's shareholder treatment is put at 7.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 29% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.7/1035% of the headline grade · 1 of 3 filed, 2 estimated

Financial health

SI estimate
5.1/10

Is it financially healthy right now?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 480 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
The newest annual statements on file are more than two years old, so the desk assumes the typical reading of its industry family, the median of 480 members with one.
What the record cannot read
The newest annual statements on file are more than two years old.
How it was reasoned
family median, 480 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: NovaBridge Biosciences's financial health is put at 5.1 of 10 with a confidence of 20 of 100, because the newest annual statements on file are more than two years old, so the desk assumes the typical reading of its industry family, the median of 480 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Industry position

as filed
0.9/10

How strong is its position in its industry?

bottom 9% of 315 in its family; net margin -5302%.

weight 22% of this tense · 9th percentile among 315 sector filers · read for its customers

From the record

NovaBridge Biosciences' standing among 315 graded names in its industry family: revenue of CNY 28 million in fiscal 2023 is not ranked by size, since the family reports in another currency; a net margin of -5302% ranks in the bottom 15%; revenue growth of -73.9% a year over the last 3 filed years ranks in the bottom 4% (its annual reports).

What it rests on

  • net margin-5302.0%bottom 15% of its family
  • three-year revenue growth-73.9%bottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
0.4/10

What are the people in charge doing?

SI estimate 0.4/10, confidence 35 of 100 (one part).

weight 33% of this tense · 4th percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the chief executive's years under the title, which ranks in the bottom 4% of 415 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: the chief executive's years on the record, the one part on file, ranked among 415 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: NovaBridge Biosciences's leadership is put at 0.4 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the bottom 4% of 415 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.9/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
8.6/10

How much room does it have to grow?

top 14% of 273 in its family for room to expand.

weight 33% of this tense · 86th percentile among 273 sector filers · read for itself

From the record

NovaBridge Biosciences' room to grow, from the newest filed statements (fiscal 2023): cash of CNY 2.2 billion against no long-term debt tagged leaves 84.2% of its assets as net cash, top 15% of its family; research spending of 2932.4% of revenue (top 13%) (its annual report).

What it rests on

  • cash less debt against assets84.2%top 15% of its family
  • research spending against revenue2932.4%top 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
5.6/10

What could actually drive growth from here?

top 44% of 306 in its family for growth drivers.

weight 45% of this tense · 56th percentile among 306 sector filers · read for its customers

From the record

NovaBridge Biosciences' growth drivers, from the filed years to fiscal 2023: revenue grew -73.9% a year over the last three filed years against -73.9% over all 4, speeding up (top 40% of its family); research spending grew -6.3% a year (bottom 38%); capital spending grew 12.3% a year (top 29%) (its annual reports). NovaBridge Biosciences tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 40% of its family
  • three-year growth of research spending-6.3%bottom 38% of its family
  • three-year growth of capital spending12.3%top 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
2.5/10

Did its newest year beat what its own record pointed to?

bottom 25% of 233 in its family for expectations against reality.

weight 22% of this tense · 25th percentile among 233 sector filers · read for its shareholders

From the record

NovaBridge Biosciences' newest year against its own record: net income of CNY 1.5 billion against a prior three-year average of CNY 1.5 billion (bottom 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 8%) (its annual reports).

What it rests on

  • net income against the prior three years' average-1%bottom 41% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NBP · research, not advice